Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Govind Nair PhD

Govind Nair PhD

Director, Quantitative MRI Core Facility, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland

Govind Nair (Bhagavatheeshwaran) earned his Bachelor of Technology in Biomedical Engineering from Cochin University of Science and Technology in India and his Master of Science in Biomedical Engineering from Drexel University in Philadelphia. He earned his Ph.D. in Biomedical Engineering and Medical Physics from Worcester Polytechnic Institute and University of Massachusetts where he studied and developed Magnetic Resonance Imaging techniques for imaging the retina. During his postdoctoral fellowship with Drs. Xiaoping Hu and Michael Benatar at Emory University, he worked on developing specialized magnetic resonance imaging techniques and markers of disease progression in patients affected by amyotrophic lateral sclerosis (ALS). He joined the National Institutes of Health in 2011 as a Staff Scientist, and directs the quantitative MRI core facility at the NINDS.

Dr. Nair’s research focuses on techniques to improve the sensitivity and specificity of MRI in detecting changes in the neuronal microenvironment in neuroinflammatory diseases, which could help with understanding disease processes in-vivo. At present, his research focuses on developing quantitative MRI markers of disease progression in neuroinflammatory diseases such as multiple sclerosis, Human T-cell leukemia virus, type 1 or HTLV-1 associated myelopathy/tropical spastic paraparesis (HAM/TSP), Progressive multifocal leukoencephalopathy (PML), disorders with neurovascular involvement such as CADASIL and COVID-19, as well as neurocognitive impairments in HIV infection.


Dr. Nair has no relevant financial disclosures. His research is supported by the Intramural Research Program at the NINDS.